Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CDH17 CAR-T cells (Shanghai Pudong Hospital)
- Development stage
- Unknown
- Lead developer
- Shanghai Pudong Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CDH17 CAR-T cells (Shanghai Pudong Hospital) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed to target Cadherin-17 (CDH17), a cell surface protein primarily expressed in the gastrointestinal tract and frequently overexpressed in various solid tumors, including colorectal, gastric, and pancreatic cancers. Developed by Shanghai Pudong Hospital, the therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically recognizes CDH17. Once infused back into the patient following lymphodepleting chemotherapy, these engineered T cells are intended to identify and eliminate CDH17-positive malignant cells. The therapy is currently being evaluated in an exploratory Phase 1 clinical trial to assess its safety, tolerability, and preliminary anti-tumor activity in patients with advanced CDH17-positive solid tumors.
- Other names
- Anti-CDH17 CAR-T cell injectionAnti-CDH-17 CAR-T cell injectionAnti-CDH 17 CAR-T cell injection
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on anti-CDH17 CAR-T cells (Shanghai Pudong Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CDH17 CAR-T cells (Shanghai Pudong Hospital).